Navigation Links
A High-Density Lipoprotein Raising Drug That Has a Lower Discontinuation Rate Than That of Extended Release Niaspan Would Earn a 20 Percent Patient Share in the Dyslipidemia Drug Market
Date:7/29/2008

Crestor Will Remain the Clinical Gold Standard Drug Through 2016, According

to a New Report from Decision Resources

WALTHAM, Mass., July 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug that raises high-density lipoprotein cholesterol and has a lower discontinuation rate than that of Abbott's Niaspan ER (extended release) would earn a 20 percent patient share in the treatment of dyslipidemia, according to surveyed endocrinologists.

The new report entitled Dyslipidemia: Blockbuster Potential for Agents that Target HDL finds that although lowering low-density lipoprotein cholesterol levels is at the forefront of treating dyslipidemia, researchers are now aware that increasing high-density lipoprotein cholesterol levels may also help reduce cardiovascular risk.

The report also finds that surveyed endocrinologists do not expect any therapy under development to displace AstraZeneca's Crestor as the Decision Resources' proprietary clinical gold standard for dyslipidemia through 2016. Although some therapies in development hold promise, most have efficacy, safety and tolerability, and/or delivery features that merit inferior scores compared with Crestor.

"For the majority of end points, endocrinologists we surveyed perceive the statin class to be very similar," said Graeme Green, Ph.D., analyst at Decision Resources. "However Crestor positively differentiates itself in its greater ability to improve low- and high-density lipoprotein cholesterol levels."

About the Report

Dyslipidemia: Blockbuster Potential for Agents that Target HDL is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign
2. Cost of raising a child with special needs: Where does your state rank?
3. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow in Indianapolis is Participating
4. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow in Cincinnati is Participating
5. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in Texas Participating
6. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in New Jersey Participating
7. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in Minnesota Participating
8. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in Michigan Participating
9. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in Colorado Participating
10. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas; Camp Bow Wow Locations in California Participating
11. Camp Bow Wow(R) Launches Fundraising Effort to Help Cure Cancer in Dogs, via Morris Animal Foundations Canine Cancer Campaign - Dogs Get Bandanas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Dublin, CA (PRWEB) , ... June 27, 2016 ... ... Community College District , the only authorized OSHA Training Institute Education Center headquartered ... illness by protecting their workers from extreme heat at their worksites. Employers ...
(Date:6/27/2016)... ... , ... "FCPX editors can now reveal their media with growing colorful split ... Austin - CEO of Pixel Film Studios. , ProSlice Color brings the split ... now reveal the media of their split screens with growing colorful panels. , ProSlice ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... today its affiliation with Tennessee Counseling Association. This new relationship allows ... the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/27/2016)... ... 2016 , ... A revolution is underway. Brooklyn-based company, ... for the millions of people who require these medical transport services annually. ... the use of technology. Now, SmartEMS has put forth an industry-changing app that ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology: